Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children
Background Next-generation, higher-valency pneumococcal conjugate vaccines (PCVs), 15-valent PCV V114 and 20-valent PCV (PCV20), have been assessed by comparing their immune responses across serotypes shared with the 13-valent PCV (PCV13). Without efficacy or real-world vaccine effectiveness (VE) it...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2023.2292773 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846141407788531712 |
|---|---|
| author | Josiah Ryman Jeffrey R. Sachs Ka Lai Yee Natalie Banniettis Jessica Weaver Thomas Weiss |
| author_facet | Josiah Ryman Jeffrey R. Sachs Ka Lai Yee Natalie Banniettis Jessica Weaver Thomas Weiss |
| author_sort | Josiah Ryman |
| collection | DOAJ |
| description | Background Next-generation, higher-valency pneumococcal conjugate vaccines (PCVs), 15-valent PCV V114 and 20-valent PCV (PCV20), have been assessed by comparing their immune responses across serotypes shared with the 13-valent PCV (PCV13). Without efficacy or real-world vaccine effectiveness (VE) it becomes important to relate IgG titers to VE to aid in the interpretation of the immune response elicited by V114 and PCV20.Methods We estimated the protective antibody concentrations for each serotype in 7-valent PCV (PCV7) and PCV13 which were then used to predict the serotype-specific VE for each PCV7 and PCV13 non PCV7 serotype present in V114 and PCV20.Results The predicted effectiveness of V114 was comparable to PCV7 and PCV13 for 11 of the 13 shared serotypes (1, 4, 5, 6B, 7F, 9 V, 14, 18C, 19A, 19F, and 23F), with improved effectiveness against serotype 3 and decreased effectiveness against serotype 6A. PCV20 had predicted effectiveness comparable to PCV7 and PCV13 for 7 of the 13 shared serotypes (5, 6A, 7F, 9 V, 18C, 19F, and 23F), with decreased effectiveness against the remaining serotypes (1, 3, 4, 6B, 14, and 19A).Conclusions Prediction of serotype-specific VE values suggests that V114 retains greater effectiveness than PCV20 toward most serotypes present in PCV7 and PCV13. |
| format | Article |
| id | doaj-art-95e52e182b40446d82a5d7caa306b2c9 |
| institution | Kabale University |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-95e52e182b40446d82a5d7caa306b2c92024-12-04T09:49:48ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-01231606810.1080/14760584.2023.2292773Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in childrenJosiah Ryman0Jeffrey R. Sachs1Ka Lai Yee2Natalie Banniettis3Jessica Weaver4Thomas Weiss5Quantitative Pharmacology and Pharmacometrics, Rahway, NJ, USAQuantitative Pharmacology and Pharmacometrics, Rahway, NJ, USAQuantitative Pharmacology and Pharmacometrics, Rahway, NJ, USAClinical Research, Rahway, NJ, USACenter for Observational and Real-World Evidence,Merck & Co, Inc, Rahway, NJ, USACenter for Observational and Real-World Evidence,Merck & Co, Inc, Rahway, NJ, USABackground Next-generation, higher-valency pneumococcal conjugate vaccines (PCVs), 15-valent PCV V114 and 20-valent PCV (PCV20), have been assessed by comparing their immune responses across serotypes shared with the 13-valent PCV (PCV13). Without efficacy or real-world vaccine effectiveness (VE) it becomes important to relate IgG titers to VE to aid in the interpretation of the immune response elicited by V114 and PCV20.Methods We estimated the protective antibody concentrations for each serotype in 7-valent PCV (PCV7) and PCV13 which were then used to predict the serotype-specific VE for each PCV7 and PCV13 non PCV7 serotype present in V114 and PCV20.Results The predicted effectiveness of V114 was comparable to PCV7 and PCV13 for 11 of the 13 shared serotypes (1, 4, 5, 6B, 7F, 9 V, 14, 18C, 19A, 19F, and 23F), with improved effectiveness against serotype 3 and decreased effectiveness against serotype 6A. PCV20 had predicted effectiveness comparable to PCV7 and PCV13 for 7 of the 13 shared serotypes (5, 6A, 7F, 9 V, 18C, 19F, and 23F), with decreased effectiveness against the remaining serotypes (1, 3, 4, 6B, 14, and 19A).Conclusions Prediction of serotype-specific VE values suggests that V114 retains greater effectiveness than PCV20 toward most serotypes present in PCV7 and PCV13.https://www.tandfonline.com/doi/10.1080/14760584.2023.2292773Pneumococcal vaccinesStreptococcus pneumoniaechild, preschoolantibodies, bacterialprotective concentrationmodeling and simulation |
| spellingShingle | Josiah Ryman Jeffrey R. Sachs Ka Lai Yee Natalie Banniettis Jessica Weaver Thomas Weiss Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children Expert Review of Vaccines Pneumococcal vaccines Streptococcus pneumoniae child, preschool antibodies, bacterial protective concentration modeling and simulation |
| title | Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children |
| title_full | Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children |
| title_fullStr | Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children |
| title_full_unstemmed | Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children |
| title_short | Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children |
| title_sort | predicted serotype specific effectiveness of pneumococcal conjugate vaccines v114 and pcv20 against invasive pneumococcal disease in children |
| topic | Pneumococcal vaccines Streptococcus pneumoniae child, preschool antibodies, bacterial protective concentration modeling and simulation |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2023.2292773 |
| work_keys_str_mv | AT josiahryman predictedserotypespecificeffectivenessofpneumococcalconjugatevaccinesv114andpcv20againstinvasivepneumococcaldiseaseinchildren AT jeffreyrsachs predictedserotypespecificeffectivenessofpneumococcalconjugatevaccinesv114andpcv20againstinvasivepneumococcaldiseaseinchildren AT kalaiyee predictedserotypespecificeffectivenessofpneumococcalconjugatevaccinesv114andpcv20againstinvasivepneumococcaldiseaseinchildren AT nataliebanniettis predictedserotypespecificeffectivenessofpneumococcalconjugatevaccinesv114andpcv20againstinvasivepneumococcaldiseaseinchildren AT jessicaweaver predictedserotypespecificeffectivenessofpneumococcalconjugatevaccinesv114andpcv20againstinvasivepneumococcaldiseaseinchildren AT thomasweiss predictedserotypespecificeffectivenessofpneumococcalconjugatevaccinesv114andpcv20againstinvasivepneumococcaldiseaseinchildren |